Daptomycin

Ozaras R., TABAK Ö. F.

KLIMIK JOURNAL, cilt.23, sa.2, ss.35-38, 2010 (ESCI, Scopus) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 23 Sayı: 2
  • Basım Tarihi: 2010
  • Doi Numarası: 10.5152/kd.2010.12
  • Dergi Adı: KLIMIK JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.35-38
  • Anahtar Kelimeler: Daptomycin, bacteremia, skin infection, endocarditis, Staphylococcus aureus
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Infections due to Gram-positive microorganisms are increasing all over the world. Treatment options in infections caused by resistant Gram-positive bacteria are limited. Daptomycin is the fi rst member of cyclic lipopeptide agents. Its spectrum of activity is the Gram-positive organisms, including resistant species such as methicillin-resistant Staphylococcus aureus, vancomyc-in-intermediate S. aureus, vancomycin-resistant S. aureus, and vancomycin- resistant enterococci. Daptomycin has been approved for the treatment of complicated skin and soft tissue infections, S. aureus bacteremia and right-sided infective endocarditis. The recommended dosing regimen is 4-6 mg/kg IV once daily. Dose adjustment is necessary in renal failure. Primary toxicity of daptomycin is reversible dose-related myalgias and weakness.